You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Cyclic RGDfK Peptide Functionalized Polymeric Nanocarriers for Targeting Gemcitabine to Ovarian Cancer Cells
|
|---|---|
| Published in |
Molecular Pharmaceutics, March 2016
|
| DOI | 10.1021/acs.molpharmaceut.5b00935 |
| Pubmed ID | |
| Authors |
Hitesh Kulhari, Deep Pooja, Raju Kota, T. Srinivasa Reddy, Rico F. Tabor, Ravi Shukla, David J. Adams, Ramakrishna Sistla, Vipul Bansal |
| Abstract |
Current cancer chemotherapies commonly suffer from non-specificity, drug resistance, poor bioavailability and narrow therapeutic indices. To achieve the optimum drug efficacy, we designed a polymeric drug delivery system for targeted intracellular delivery of a clinically-approved, water-soluble anticancer drug, gemcitabine hydrochloride (GEM). We utilised the unique ability of a cyclic pentapeptide cRGDfK to specifically target αvβ3 integrin receptors that are over-expressed on SKOV-3 human ovarian cancer cells. This significantly increased the effective intracellular drug concentration even at low doses, thereby remarkably improving the chemotherapeutic potential of GEM. cRGDfK-conjugated, GEM-loaded nanoparticles reduced the nonspecific hemolytic cytotoxicity of the drug, simultaneously influencing intracellular processes such as mitochondrial membrane potential (DΨm), reactive oxygen species (ROS) levels and apoptosis, thereby favourably influencing drug anti-proliferative efficacy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 26% |
| Researcher | 7 | 18% |
| Student > Master | 6 | 16% |
| Student > Doctoral Student | 3 | 8% |
| Professor | 2 | 5% |
| Other | 3 | 8% |
| Unknown | 7 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 24% |
| Medicine and Dentistry | 5 | 13% |
| Chemistry | 5 | 13% |
| Agricultural and Biological Sciences | 2 | 5% |
| Engineering | 2 | 5% |
| Other | 6 | 16% |
| Unknown | 9 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 March 2016.
All research outputs
#18,444,553
of 22,852,911 outputs
Outputs from Molecular Pharmaceutics
#2,783
of 4,118 outputs
Outputs of similar age
#220,433
of 301,265 outputs
Outputs of similar age from Molecular Pharmaceutics
#58
of 72 outputs
Altmetric has tracked 22,852,911 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,118 research outputs from this source. They receive a mean Attention Score of 4.6. This one is in the 4th percentile – i.e., 4% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 301,265 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 72 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.